Participants included in the review
Healthy individuals, secondary prevention studies and studies among subgroups such as diabetic patients were excluded from the systematic review; some secondary prevention studies were discussed in a 'narrative' review. The age range and other demographic characteristics of the participants in the included studies were not provided. Two of the larger studies enrolled men only, while three enrolled high-risk individuals (smoking middle-aged men in Finland), smokers and asbestosis workers in the USA, and people with at least one cardiovascular risk factor or aged over 65 years in Italy. One study was conducted in low-risk health professionals from the USA, and another in a Chinese population where micronutrient deficiencies were common.
Outcomes assessed in the review Cardiovascular disease, including ischaemic heart disease deaths or events, or stroke, was assessed. Adverse events were also reported. The outcomes were not clearly defined, and all-cause mortality was not considered.
How were decisions on the relevance of primary studies made?
The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection.
Assessment of study quality
The author states that the validity of the studies was assessed against strict quality criteria and ranked into three categories: low, intermediate or high scientific quality. The quality criteria were not described, although a reference to a None of the RCTs showed any beneficial effect of antioxidant supplementation on cardiovascular disease. The pooled ORs were 1.02 (95% CI: 0.96, 1.08) for beta-carotene, 0.96 (95% CI: 0.88, 1.04) for alpha-tocopherol and 0.98 (95% CI: 0.75, 1.26) for ascorbic acid. In one study, there was a significantly increased risk for fatal or nonfatal intracerebral and subarachnoid haemorrhage in participants taking alpha-tocopherol (results not presented). Two trials found an association between the intake of carotene supplements and an increased risk of lung cancer in cigarette smokers (results not presented). These findings from the RCTs contradict the results of the observational (case-control and cohort) studies, which mostly identified reductions in the risk of cardiovascular events for participants with high plasma levels of these nutrients.
Authors' conclusions
In the RCTs, antioxidant vitamins as food supplements had no beneficial effects in the primary prevention of myocardial infarction and stroke. The reported increased risks of intracerebral and subarachnoid haemorrhage during treatment with carotene and tocopherol may caution against the use of antioxidants in healthy people. Only two studies of ascorbic acid were identified, but the results were consistent with an earlier systematic review. The existing RCTs had limitations: most were not designed specifically to test the protective effect on cardiovascular disease outcomes; some of the largest trials included only smokers, and the relationship between smoking and oxidation is complex; the duration of treatment may have been too short, or the doses of vitamins too low; synthetic antioxidants may differ from natural ones in their effects on cardiovascular diseases; specific antioxidants have been used alone, or in combinations of two, when there may be advantages to a mixture.
CRD commentary
This review covered an important topic area, and reviewed observational and experimental evidence for antioxidant nutrients and cardiovascular disease. The author described some relevant ongoing studies (table 6), which was useful, although it is unclear how these were identified. Limitations of the primary studies were described in detail in the 'Discussion' section, although many methodological aspects were unclear. The search strategy was limited to MEDLINE and the Science Citation Index, and studies published after 1989. Other databases, such as EMBASE, should have been searched and earlier studies included. The author did not state whether any language restrictions were applied to the searches. The methods used to assess study eligibility, extract the data and assess quality were not described in sufficient detail. More details of the included RCTS are also required, such as the age ranges of the participants, doses
